SOUTH SAN FRANCISCO, Calif., Dec. 11, 2019 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in

SOUTH SAN FRANCISCO, Calif., Dec. 10, 2019 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in

SOUTH SAN FRANCISCO, Calif. , Dec. 04, 2019 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in

SOUTH SAN FRANCISCO, Calif. and SEOUL, South Korea, Dec. 03, 2019 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Oct. 30, 2019-- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in

-- Once-Daily, Orally Administered CCR4 Antagonist Blocks Recruitment of Th2 Inflammatory Immune Cells -- -- Potential to Treat Allergic Inflammatory Diseases Including Atopic Dermatitis -- SOUTH SAN FRANCISCO, Calif.--( BUSINESS WIRE )--RAPT Therapeutics, Inc., a clinical-stage immunology-based

SOUTH SAN FRANCISCO, Calif.--( BUSINESS WIRE )--RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company developing oral small molecules for oncology and inflammatory diseases, today announced the addition of Wendye Robbins, M.D., president and CEO of Blade Therapeutics,

SOUTH SAN FRANCISCO, Calif.--( BUSINESS WIRE )--RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company developing oral small molecules for oncology and inflammatory diseases, today announced the promotion of Dirk Brockstedt, Ph.D., to chief scientific officer and David

SOUTH SAN FRANCISCO, Calif.--( BUSINESS WIRE )--RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company developing oral small molecules for oncology and inflammatory diseases, today announced that Emma Guttman-Yassky, M.D., Ph.D., from the Department of Dermatology at

SOUTH SAN FRANCISCO, Calif.--( BUSINESS WIRE )--RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company developing oral small molecules for oncology and inflammatory diseases, today announced that it secured an additional $37 million in an extension of its Series C